EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy

Arnoldo Piccardo iD, Giorgio Treglia, Francesco Fiz, Zvi Bar-Sever, Gianluca Bottoni, Lorenzo Biassoni, Lise Borgwardt, Bart de Keizer, Nina Jehanno, Egesta Lopci, Lars Kurch, Michela Massollo und 8 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-023-06486-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Arnoldo Piccardo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura Delle Cappuccine 14, 16128, Genoa, Italy. arnoldo.piccardo@galliera.it. Hauptthemen laut MEDLINE: Neuroblastoma, Radiopharmaceuticals. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [ 123 I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpretation. Many PET catecholaminergic radiotracers have been proposed as a replacement for [ 123 I]-mIBG, however they have not yet made it into clinical practice. We aimed to review the available literature comparing head-to-head [ 123 I]-mIBG with the most common PET catecholaminergic radiopharmaceuticals.

Methods

We searched the PubMed database for studies performing a head-to-head comparison between [ 123 I]-mIBG and PET radiopharmaceuticals including meta-hydroxyephedrine ([ 11 C]C-HED), 18 F-18F-3,4-dihydroxyphenylalanine ([ 18 F]DOPA) [ 124 I]mIBG and Meta -[18F]fluorobenzylguanidine ([ 18 F]mFBG). Review articles, preclinical studies, small case series (< 5 subjects), case reports, and articles not in English were excluded. From each study, the following characteristics were extracted: bibliographic information, technical parameters, and the sensitivity of the procedure according to a patient-based analysis (PBA) and a lesion-based analysis (LBA).

Results

Ten studies were selected: two regarding [ 11 C]C-HED, four [ 18 F]DOPA, one [ 124 I]mIBG, and three [ 18 F]mFBG. These studies included 181 patients (range 5–46). For the PBA, the superiority of the PET method was reported in two out of ten studies (both using [ 18 F]DOPA). For LBA, PET detected significantly more lesions than scintigraphy in seven out of ten studies.

Conclusions

PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaRadiopharmaceuticalsChildHumans3-IodobenzylguanidineDihydroxyphenylalaninePositron Emission Tomography Computed TomographyPositron-Emission Tomography

Stichwörter der Autor:innen

CatecholamineGuidelineNeuroblastomaPET-CTPaediatric PET[124I]MIBG, 18F-MFBG, 11C-HED[18F]F-DOPA

Substanzen

3-IodobenzylguanidineDihydroxyphenylalaninefluorodopa F 18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura Delle Cappuccine 14, 16128, Genoa, Italy. arnoldo.piccardo@galliera.it.
  • Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
  • Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
  • Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura Delle Cappuccine 14, 16128, Genoa, Italy.
  • Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital, Tübingen, Germany.

ORCID-Profile: Arnoldo Piccardo

Zitieren

APA

Piccardo, A., Treglia, G., Fiz, F., Bar-Sever, Z., Bottoni, G., Biassoni, L., Borgwardt, L., de Keizer, B., Jehanno, N., Lopci, E., Kurch, L., Massollo, M., Nadel, H., Roca Bielsa, I., Shulkin, B., Vali, R., De Palma, D., Cecchin, D., Santos, A. I., & Zucchetta, P. (2024). The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06486-9

Vancouver

Piccardo A, Treglia G, Fiz F, Bar-Sever Z, Bottoni G, Biassoni L, et al. The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-023-06486-9

BibTeX
@article{Piccardo2024,
  author = {Piccardo, Arnoldo and Treglia, Giorgio and Fiz, Francesco and Bar-Sever, Zvi and Bottoni, Gianluca and Biassoni, Lorenzo and Borgwardt, Lise and de Keizer, Bart and Jehanno, Nina and Lopci, Egesta and Kurch, Lars and Massollo, Michela and Nadel, Helen and Roca Bielsa, Isabel and Shulkin, Barry and Vali, Reza and De Palma, Diego and Cecchin, Diego and Santos, Ana Isabel and Zucchetta, Pietro},
  title = {The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-023-06486-9}
}
Kostenlos starten →